135
Participants
Start Date
March 31, 2021
Primary Completion Date
July 5, 2022
Study Completion Date
July 5, 2022
mRNA-1273
Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike protein of the Wuhan-Hu-1 strain of SARS-CoV-2. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and PEG2000 DMG.
mRNA-1273.351
Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the pre fusion stabilized spike protein of the B.1.351 variant SARS-CoV-2 strain. mRNA-1273.351 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and PEG2000 DMG.
The Hope Clinic of Emory University, Decatur
Cincinnati Children's Hospital Medical Center Vaccine Research Center, Cincinnati
Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center, Nashville
Kaiser Permanente Washington Health Research Institute, Seattle
ModernaTX, Inc.
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH